Adamas Pharmaceuticals reported 29.15M in Selling and Administration Expenses for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Abbvie ABBV:US $ 3.07B 228M
Acadia Pharmaceuticals ACAD:US $ 96.79M 14.87M
Acorda Therapeutics ACOR:US $ 32.37M 100K
Adamas Pharmaceuticals ADMS:US 29.15M 2.51M
Aerie Pharmaceuticals AERI:US $ 34.54M 1.94M
Aptinyx Inc APTX:US $ 5.07M 94K
Biocryst Pharmaceuticals BCRX:US $ 26.32M 4.21M
Flexion Therapeutics FLXN:US $ 27.41M 189K
GlaxoSmithKline GSK:LN 2.5B 183M
Glaxosmithkline GSK:US 2.5B 183M
Gw Pharmaceuticals GWPH:US 101.05M 2.71M
Heron Therapeutics HRTX:US $ 33.16M 8.35M
Intra Cellular Therapies ITCI:US $ 69.85M 17.27M
Marinus Pharmaceuticals MRNS:US 6.83M 3.55M
Merk MRK:US $ 2.25B 376M
Neurocrine Biosciences NBIX:US $ 143.2M 14.2M
Novartis NOVN:VX 3.71B 190M
Omeros OMER:US $ 21.56M 3.51M
Prothena PRTA:US 11.03M 93K
Revance Therapeutics RVNC:US $ 49.01M 937K
Teva Pharmaceutical TEVA:IT 832M 16M
Zogenix ZGNX:US $ 33.88M 2.61M